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I read with interest the summary of the
hotline sessions of this year’s ESC Congress
provided by Bergman et al.
1 The paper dis-
cusses the results of the F.I.R.E. study, which
investigated the effect of a new drug, FX06
(ﬁbrin-derived peptide Bb15-42), for the pre-
vention of ischaemia/reperfusion injury in the
setting of acute STEMI, which we presented at
hotline III. We think that the conclusion given
in the EHJ that FX06 failed to signiﬁcantly
reduce reperfusion injury parameters in this
STEMI population does not provide a fair jud-
gement to the interesting results obtained in
this trial.
There is ample evidence from the literature
that even small reductions in permanently
damaged myocardium measured acutely
after STEMI have the potential to provide sus-
tained beneﬁt for patients.
2 This has been
speciﬁcally demonstrated for microvascular
obstruction by several groups, who found
this parameter to by an independent predic-
tor of long-term patient outcome.
3,4 In this
context, the reduction of the mass of unreco-
verable myocardium by .50% is a very
remarkable ﬁnding. It should also be noted
that both the incidence and extent of micro-
vascular obstructions trended lower in
FX06-treated patients, even though the differ-
ence did not reach statistical signiﬁcance.
Interestingly, there were also trends in
favour of FX06 in cardiac events, including
cardiac death and new onset heart failure,
which are encouraging and warrant further
investigation in larger trials.
We would also like to put the apparent
lack of difference to placebo in scar mass
measured at 4 months into perspective.
Patients were followed for 4 months primarily
for safety reasons, looking for cardiac death
and MACE. It is important to take into
account that most MACE as a sequel of the
index infarction occur early after PCI, so the
acute size of the infarct has very strong rel-
evance for patient outcome. For instance, in
the recently published APEX-AMI trial, the
combined event rate of cardiac death, CHF,
and shock was 9.1% at 30 days, and increased
only marginally to 10.2% at 90 days.
5 Second
CMR imaging at 4 months was done in the
F.I.R.E. trial to assess whether FX06 treatment
had an effect on scar formation; however, it
was unlikely that a signiﬁcant effect would
be demonstrated, since this was just a single
bolus treatment and we did not control for
confounding effects and medication during
the follow-up period. Scar mass was indeed
numerically, but not signiﬁcantly, lower at
the 4 month time point compared with
placebo. The study design did not allow for
any evaluation of infarct expansion or shrink-
age with respect to necrotic core size at 5
days and scar size at 4 months. More impor-
tantly, 15% of patients (FX06 14, placebo
16) did not return for repeat CMR at 4
months. This included, of course, patients
who died from cardiac cause, ﬁve in the
placebo group and only two in the FX06
group; this unequal loss to follow up leads
to a distortion because patients who died
could be considered of having large infarc-
tions. The follow-up data are further dis-
torted by the likelihood that more large
infarcts were followed up in the FX06-
treated group. Analysis of only patients with
paired CMR images (completers) showed no
difference in infarct size relative to LV mass
in patients treated with FX06 at Day 5 and
4 months, whereas shrinkage by approxi-
mately 50% was observed in the placebo
group. However, analysis of completers only
introduces another selection bias. It is poss-
ible that the infarcts of patients treated with
FX06 were already so small that there was
not much apparent shrinkage during remodel-
ling (unlike under placebo). Remodelling with
scar shrinkage is actually an ominous sign that
may lead to wall thinning, so the lack of
shrinkage in the FX06 patients may be seen
as beneﬁcial.
In summary, we would like to emphasize
that the F.I.R.E. study as an exploratory trial
provided a very consistent set of data
suggesting a cardioprotective role of FX06
achieved by a reduction of ischaemia/reperfu-
sion injury. The full study results have just
been published.
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